Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

• मुख्य लेखकों: Galve-Calvo E (लेखक), González-Haba E (लेखक), Gostkorzewicz J (लेखक), Martínez I (लेखक), Pérez-Mitru A (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Dove Medical Press, 2018-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; 3Novartis Farmacéutica, S.A., Health Economics an...